CHEST Physician
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
SWIFT studies show promise of IL-5-targeted twice-yearly option for severe asthma with an eosinophilic phenotype
Lauren E. Eggert, MD, said depemokimab could be a more convenient therapy choice for both patients and providers.
-
GOLDen handcuffs: Beyond spirometry in COPD
When it comes to diagnosing COPD, clinicians must look beyond spirometry and physiology to see a patient fully.
-
Advancements in pediatric airway evaluation
Pediatric airway anatomy evaluation continues to evolve with the development of newer technologies such as dynamic volumetric CT scans.
-
Inspiring the next CHEST leader
CHEST President John Howington, MD, MBA, FCCP, found his home within CHEST, and he hopes that you will too.
-
Newest Bridging Specialties program focuses on team-based care in PH-ILD
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages collaboration across disciplines and provides assets designed for practical use.
-
Top reads from the CHEST journal portfolio – June 2025
Editorial Board members share their insights on journal articles about observation vs surgery in pulmonary subsolid nodules, initial opioid exposure in the ICU, and clinical outcomes of cardiac arrythmias in PAH.
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
-
Study to test efficacy of tezepelumab for treating asthma exacerbations in the emergency department
Diego J. Maselli, MD, FCCP, said the TERAA trial will provide needed evidence on the use of biologics in the acute care setting.
